Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
$0.27
-0.5%
$0.27
$0.20
$1.48
$73.10M2.181.63 million shs519,720 shs
Agenus Inc. stock logo
AGEN
Agenus
$5.92
+14.3%
$4.37
$1.38
$18.74
$142.02M1.51703,191 shs1.59 million shs
Alector, Inc. stock logo
ALEC
Alector
$1.72
+4.2%
$1.38
$0.87
$6.78
$164.99M0.74836,038 shs710,580 shs
Cellectis S.A. stock logo
CLLS
Cellectis
$1.65
+1.5%
$1.49
$1.10
$2.43
$90.32M2.91142,909 shs33,641 shs
Passage Bio, Inc. stock logo
PASG
Passage Bio
$0.40
-9.9%
$0.38
$0.26
$1.33
$27.41M1.67381,672 shs1.26 million shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
-0.54%+9.28%-1.08%+23.39%-76.95%
Agenus Inc. stock logo
AGEN
Agenus
+14.29%-0.17%+10.24%+248.24%-61.31%
Alector, Inc. stock logo
ALEC
Alector
+4.24%+16.61%+8.18%+81.05%-65.74%
Cellectis S.A. stock logo
CLLS
Cellectis
+1.54%+4.10%+17.02%+14.58%-15.38%
Passage Bio, Inc. stock logo
PASG
Passage Bio
-9.86%-13.77%-17.10%+9.66%-51.60%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
2.429 of 5 stars
3.15.00.00.02.10.80.0
Agenus Inc. stock logo
AGEN
Agenus
4.3652 of 5 stars
3.24.00.04.62.51.70.6
Alector, Inc. stock logo
ALEC
Alector
4.1105 of 5 stars
3.13.00.04.52.62.50.0
Cellectis S.A. stock logo
CLLS
Cellectis
3.1593 of 5 stars
3.53.00.00.02.62.50.6
Passage Bio, Inc. stock logo
PASG
Passage Bio
2.8264 of 5 stars
3.53.00.00.01.11.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
2.29
Hold$1.35392.77% Upside
Agenus Inc. stock logo
AGEN
Agenus
2.33
Hold$14.00136.49% Upside
Alector, Inc. stock logo
ALEC
Alector
2.14
Hold$4.00132.56% Upside
Cellectis S.A. stock logo
CLLS
Cellectis
3.00
Buy$4.00142.42% Upside
Passage Bio, Inc. stock logo
PASG
Passage Bio
3.00
Buy$7.501,786.79% Upside

Current Analyst Ratings Breakdown

Latest ADAP, ALEC, PASG, CLLS, and AGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$1.50 ➝ $0.50
6/24/2025
Passage Bio, Inc. stock logo
PASG
Passage Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00
6/4/2025
Agenus Inc. stock logo
AGEN
Agenus
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$4.00 ➝ $6.00
6/4/2025
Agenus Inc. stock logo
AGEN
Agenus
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$25.00
5/14/2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$1.50 ➝ $1.00
5/14/2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$1.00 ➝ $0.46
5/13/2025
Agenus Inc. stock logo
AGEN
Agenus
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
5/13/2025
Agenus Inc. stock logo
AGEN
Agenus
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$3.00 ➝ $4.00
5/13/2025
Cellectis S.A. stock logo
CLLS
Cellectis
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.00
5/9/2025
Alector, Inc. stock logo
ALEC
Alector
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $10.00
4/30/2025
Agenus Inc. stock logo
AGEN
Agenus
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
$178.03M0.41N/AN/A$0.05 per share5.49
Agenus Inc. stock logo
AGEN
Agenus
$99.52M1.63N/AN/A($13.06) per share-0.45
Alector, Inc. stock logo
ALEC
Alector
$100.56M1.71N/AN/A$1.29 per share1.33
Cellectis S.A. stock logo
CLLS
Cellectis
$49.22M1.86N/AN/A$2.36 per share0.70
Passage Bio, Inc. stock logo
PASG
Passage Bio
N/AN/AN/AN/A$0.99 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
-$70.81M-$0.27N/AN/AN/A-38.91%-163.73%-23.65%8/11/2025 (Estimated)
Agenus Inc. stock logo
AGEN
Agenus
-$227.21M-$8.67N/AN/AN/A-196.12%N/A-82.33%8/6/2025 (Estimated)
Alector, Inc. stock logo
ALEC
Alector
-$119.05M-$1.26N/AN/AN/A-139.74%-100.58%-25.15%8/6/2025 (Estimated)
Cellectis S.A. stock logo
CLLS
Cellectis
-$36.76M-$0.86N/AN/AN/A-114.82%-62.55%-21.19%8/5/2025 (Estimated)
Passage Bio, Inc. stock logo
PASG
Passage Bio
-$64.77M-$1.02N/AN/AN/AN/A-93.59%-59.65%8/14/2025 (Estimated)

Latest ADAP, ALEC, PASG, CLLS, and AGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Alector, Inc. stock logo
ALEC
Alector
-$0.45N/AN/AN/A$2.76 millionN/A
8/5/2025N/A
Cellectis S.A. stock logo
CLLS
Cellectis
-$0.15N/AN/AN/A$10.07 millionN/A
5/13/2025Q1 2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
-$0.18-$0.18N/A-$0.18$6.55 million$7.29 million
5/13/2025Q1 2025
Passage Bio, Inc. stock logo
PASG
Passage Bio
-$0.24-$0.25-$0.01-$0.25N/AN/A
5/12/2025Q1 2025
Agenus Inc. stock logo
AGEN
Agenus
-$1.61-$1.03+$0.58-$1.03$26.38 million$24.07 million
5/12/2025Q1 2025
Cellectis S.A. stock logo
CLLS
Cellectis
-$0.1540-$0.18-$0.0260-$0.18$12.71 million$12.03 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
N/AN/AN/AN/AN/A
Agenus Inc. stock logo
AGEN
Agenus
N/AN/AN/AN/AN/A
Alector, Inc. stock logo
ALEC
Alector
N/AN/AN/AN/AN/A
Cellectis S.A. stock logo
CLLS
Cellectis
N/AN/AN/AN/AN/A
Passage Bio, Inc. stock logo
PASG
Passage Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
4.24
2.02
1.79
Agenus Inc. stock logo
AGEN
Agenus
N/A
0.11
0.11
Alector, Inc. stock logo
ALEC
Alector
0.10
3.34
3.34
Cellectis S.A. stock logo
CLLS
Cellectis
0.44
1.67
1.67
Passage Bio, Inc. stock logo
PASG
Passage Bio
N/A
3.74
3.74

Institutional Ownership

CompanyInstitutional Ownership
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
31.37%
Agenus Inc. stock logo
AGEN
Agenus
61.46%
Alector, Inc. stock logo
ALEC
Alector
85.83%
Cellectis S.A. stock logo
CLLS
Cellectis
63.90%
Passage Bio, Inc. stock logo
PASG
Passage Bio
53.48%

Insider Ownership

CompanyInsider Ownership
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
12.74%
Agenus Inc. stock logo
AGEN
Agenus
5.50%
Alector, Inc. stock logo
ALEC
Alector
9.10%
Cellectis S.A. stock logo
CLLS
Cellectis
16.41%
Passage Bio, Inc. stock logo
PASG
Passage Bio
5.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
490265.05 million231.28 millionOptionable
Agenus Inc. stock logo
AGEN
Agenus
44027.42 million25.91 millionOptionable
Alector, Inc. stock logo
ALEC
Alector
27099.99 million90.89 millionOptionable
Cellectis S.A. stock logo
CLLS
Cellectis
29055.58 million46.46 millionOptionable
Passage Bio, Inc. stock logo
PASG
Passage Bio
13062.15 million59.04 millionOptionable

Recent News About These Companies

Passage Bio Announces 1-for-20 Reverse Stock Split
PASG Passage Bio, Inc. - Seeking Alpha
PASSAGE BIO, INC. : Wedbush persiste à l'achat
Passage Bio price target lowered to $6 from $7 at Chardan

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adaptimmune Therapeutics stock logo

Adaptimmune Therapeutics NASDAQ:ADAP

$0.27 0.00 (-0.54%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$0.28 +0.00 (+0.26%)
As of 06:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Agenus stock logo

Agenus NASDAQ:AGEN

$5.92 +0.74 (+14.29%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$5.97 +0.05 (+0.84%)
As of 05:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Alector stock logo

Alector NASDAQ:ALEC

$1.72 +0.07 (+4.24%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$1.72 0.00 (-0.29%)
As of 05:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Cellectis stock logo

Cellectis NASDAQ:CLLS

$1.65 +0.03 (+1.54%)
Closing price 07/10/2025 03:59 PM Eastern
Extended Trading
$1.55 -0.10 (-5.82%)
As of 06:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Passage Bio stock logo

Passage Bio NASDAQ:PASG

$0.40 -0.04 (-9.86%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$0.38 -0.02 (-5.66%)
As of 06:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.